AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 43 filers reported holding AVADEL PHARMACEUTICALS PLC in Q4 2019. The put-call ratio across all filers is 0.93 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $7,769,000 | -39.8% | 1,029,012 | -66.8% | 1.04% | -56.4% |
| Q3 2019 | $12,907,000 | +43.9% | 3,102,673 | 0.0% | 2.39% | +22.3% |
| Q2 2019 | $8,967,000 | +100.7% | 3,102,673 | 0.0% | 1.95% | +111.4% |
| Q1 2019 | $4,468,000 | -44.2% | 3,102,673 | 0.0% | 0.92% | -12.3% |
| Q4 2018 | $8,005,000 | -34.7% | 3,102,673 | +11.1% | 1.05% | -41.6% |
| Q3 2018 | $12,260,000 | -26.6% | 2,792,773 | +2.5% | 1.80% | -31.4% |
| Q2 2018 | $16,702,000 | -12.7% | 2,724,663 | +3.8% | 2.63% | -11.8% |
| Q1 2018 | $19,134,000 | -10.0% | 2,624,663 | +1.3% | 2.98% | -14.2% |
| Q4 2017 | $21,252,000 | -43.3% | 2,591,721 | -27.4% | 3.47% | -37.3% |
| Q3 2017 | $37,465,000 | -17.8% | 3,568,122 | -13.7% | 5.54% | +0.1% |
| Q2 2017 | $45,592,000 | +7.2% | 4,133,464 | -5.9% | 5.54% | +7.5% |
| Q1 2017 | $42,538,000 | – | 4,394,464 | – | 5.15% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Stonepine Capital Management, LLC | 985,210 | $10,345,000 | 6.10% |
| Broadfin Capital, LLC | 3,568,122 | $37,465,000 | 5.54% |
| JW Asset Management, LLC | 444,439 | $4,667,000 | 3.42% |
| ARMISTICE CAPITAL, LLC | 1,688,000 | $17,724,000 | 2.09% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,655,494 | $38,383,000 | 1.73% |
| FALCON POINT CAPITAL, LLC | 661,490 | $6,284,000 | 0.91% |
| KNOTT DAVID M | 158,555 | $1,665,000 | 0.71% |
| Perceptive Advisors | 3,098,010 | $32,530,000 | 0.62% |
| Sio Capital Management, LLC | 91,413 | $960,000 | 0.50% |
| HEARTLAND ADVISORS INC | 700,000 | $7,350,000 | 0.48% |